The global flow cytometry market is experiencing significant growth, driven by rising demand for advanced diagnostic techniques in oncology, immunology, and infectious disease research. Increasing adoption of flow cytometry in clinical applications, such as hematological malignancies and immune system disorders, is accelerating market expansion. Technological advancements, including the development of high-throughput flow cytometry and automation, are enhancing accuracy and efficiency, fueling adoption in research and clinical settings. Additionally, the growing biopharmaceutical sector, with a focus on drug discovery and development, is boosting demand for flow cytometry in cell analysis and biomarker detection. However, the high cost of instruments and complexities associated with data analysis pose challenges to market growth.
Global Flow Cytometry Market size was valued at USD 6.40 billion in 2024 and is projected to reach USD 14.71 billion by 2032, with a CAGR of 10.9% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-flow-cytometry-market
Below are the Top Flow Cytometry Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
BD
|
BD is a leading global medical technology company specializing in diagnostics, biosciences, and medical devices. In the flow cytometry market, BD offers a comprehensive range of flow cytometers, reagents, and software solutions for research and clinical applications. The company focuses on innovation, automation, and high-throughput solutions, catering to immunology, oncology, and infectious disease research. BD's extensive distribution network and continuous investment in technological advancements strengthen its position in the market.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In January 2025, BD announced a collaboration with Biosero to integrate robotic automation into BD's flow cytometry instruments. This partnership aims to enhance drug discovery and development by enabling robotic arms to handle tasks traditionally performed manually, thereby increasing efficiency and throughput in laboratory workflows.
|
|
2.
|
Agilent Technologies, Inc.
|
Agilent Technologies is a key player in the life sciences and diagnostics industry, providing advanced analytical instruments, including flow cytometry solutions. The company offers high-performance flow cytometers designed for cell analysis in research and clinical settings. Agilent focuses on enhancing the accuracy, efficiency, and ease of use of its flow cytometry instruments while expanding its product portfolio through strategic acquisitions and collaborations.
|
|
North America, South America, Asia-Pacific, and Europe
|
In July 2024, Agilent Technologies has announced the acquisition of Canadian drug services firm BioVectra for USD 925 million. This move expands Agilent's capabilities in gene editing, specifically in manufacturing oligonucleotides and peptides, enhancing its role in RNA-based therapies and gene editing technologies like CRISPR-Cas
|
|
3.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific is a major player in the global flow cytometry market, offering a wide range of instruments, reagents, and software solutions for cell analysis. The company's flow cytometry products are widely used in drug discovery, immunology, and oncology research. Thermo Fisher’s strong R&D investments, global distribution channels, and strategic acquisitions enable it to maintain a competitive edge in the market.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2024, Thermo Fisher celebrated the ribbon-cutting of a 72,500-square-foot expansion at its Middleton campus, which will serve as a laboratory for pharmaceutical testing. The project will create 350 jobs over the next two years, with state tax credits supporting the initiative.
|
|
4.
|
Bio-Rad Laboratories, Inc.
|
Bio-Rad Laboratories is a leading provider of life science research and clinical diagnostic products, including flow cytometry solutions. The company specializes in developing compact and user-friendly flow cytometers designed for a wide range of applications, including immunology, cell biology, and microbiology. Bio-Rad focuses on enhancing data accuracy and workflow automation while expanding its global presence through strategic partnerships.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2024, Bio-Rad Laboratories introduced Annexin V conjugated to eight StarBright Dyes, enhancing the detection of early apoptotic cells via flow cytometry. This expansion offers researchers increased flexibility in multicolor immunophenotyping panels, accommodating both conventional and full-spectrum flow cytometry applications.
|
|
5.
|
Sartorius AG
|
Sartorius AG is a global pharmaceutical and laboratory equipment provider, offering advanced solutions for biopharmaceutical research and development. The company has strengthened its presence in the flow cytometry market through acquisitions and innovation in cell analysis technologies. Sartorius provides high-performance cytometry solutions tailored for bioprocessing and research applications, with a focus on automation, scalability, and high-throughput analysis.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2024, Sartorius Stedim Biotech has opened a new Center for Bioprocess Innovation in Marlborough, Massachusetts, aimed at advancing the development of next-generation therapeutics. The 63,000-square-foot facility will provide process optimization, training, and GMP suites for clinical production starting in 2025.
|
Conclusion
The global flow cytometry market is experiencing significant growth, driven by increasing demand for advanced cell analysis techniques in research, diagnostics, and drug discovery. Leading companies such as BD, Agilent Technologies, Thermo Fisher Scientific, Bio-Rad Laboratories, and Sartorius AG are focusing on technological advancements, automation, and high-throughput capabilities to enhance precision and efficiency. The market is further fueled by the rising prevalence of cancer, immunological disorders, and infectious diseases, increasing the adoption of flow cytometry in clinical and pharmaceutical applications. Strategic acquisitions, product innovations, and expanding global distribution networks are key strategies employed by market players to strengthen their competitive position. With continuous advancements in reagent development, software integration, and single-cell analysis, the flow cytometry market is poised for sustained growth in the coming years.
